JP2017531013A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531013A5
JP2017531013A5 JP2017520388A JP2017520388A JP2017531013A5 JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5 JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017520388 A JP2017520388 A JP 2017520388A JP 2017531013 A5 JP2017531013 A5 JP 2017531013A5
Authority
JP
Japan
Prior art keywords
liver disease
composition
item
fatty liver
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017520388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531013A (ja
JP6761410B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/055487 external-priority patent/WO2016061195A1/en
Publication of JP2017531013A publication Critical patent/JP2017531013A/ja
Publication of JP2017531013A5 publication Critical patent/JP2017531013A5/ja
Application granted granted Critical
Publication of JP6761410B2 publication Critical patent/JP6761410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017520388A 2014-10-15 2015-10-14 グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置 Active JP6761410B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US62/064,358 2014-10-15
US201462092041P 2014-12-15 2014-12-15
US62/092,041 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (3)

Publication Number Publication Date
JP2017531013A JP2017531013A (ja) 2017-10-19
JP2017531013A5 true JP2017531013A5 (OSRAM) 2018-11-22
JP6761410B2 JP6761410B2 (ja) 2020-09-23

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017520388A Active JP6761410B2 (ja) 2014-10-15 2015-10-14 グルココルチコイドおよびミネラル・コルチコイドレセプターアンタゴニストを使用する脂肪肝疾患の処置

Country Status (22)

Country Link
US (5) US10238659B2 (OSRAM)
EP (2) EP4353310A3 (OSRAM)
JP (1) JP6761410B2 (OSRAM)
KR (1) KR102435956B1 (OSRAM)
CN (2) CN111557942B (OSRAM)
AU (1) AU2015333645B2 (OSRAM)
BR (1) BR112017007860B1 (OSRAM)
CA (1) CA2964625C (OSRAM)
DK (1) DK3206692T3 (OSRAM)
ES (1) ES2978871T3 (OSRAM)
FI (1) FI3206692T3 (OSRAM)
IL (1) IL251729B (OSRAM)
MX (1) MX2017004943A (OSRAM)
NZ (1) NZ731060A (OSRAM)
PH (1) PH12017500710B1 (OSRAM)
PL (1) PL3206692T3 (OSRAM)
PT (1) PT3206692T (OSRAM)
RU (1) RU2718921C2 (OSRAM)
SG (1) SG11201703024VA (OSRAM)
UA (1) UA123537C2 (OSRAM)
WO (1) WO2016061195A1 (OSRAM)
ZA (1) ZA201702813B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11202011948SA (en) * 2018-06-04 2020-12-30 Corcept Therapeutics Inc Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
US11548856B2 (en) * 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US12144812B2 (en) * 2020-05-06 2024-11-19 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
WO2022140293A1 (en) * 2020-12-21 2022-06-30 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2022235647A1 (en) * 2021-05-05 2022-11-10 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ATE463479T1 (de) 2005-05-18 2010-04-15 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2007035759A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PE20090695A1 (es) 2007-04-13 2009-06-27 Schering Corp Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Similar Documents

Publication Publication Date Title
JP2017531013A5 (OSRAM)
RU2017114596A (ru) Лечение жировой болезни печени с применением антагонистов глюкокортикоидных и минералокортикоидных рецепторов
JP2014015465A5 (OSRAM)
JP2018510139A5 (OSRAM)
JP2014521688A5 (OSRAM)
JP2016505614A5 (OSRAM)
RU2018116351A (ru) Пиримидиновое соединение
JP2011137045A5 (OSRAM)
JP2020521766A5 (OSRAM)
AR072241A1 (es) Antagonistas de aminoalquilbifenilo n,n-disustituidos de receptores de prostaglandina d2 y composiciones farmaceuticas que los comprenden
JP2016516043A5 (OSRAM)
EA201400234A1 (ru) Фунгицидные замещенные 1-{2-[2-галоген-4(4-галогенфенокси)фенил]-2-алкинилоксиэтил}-1н-[1,2,4]триазолные соединения
JP2016515096A5 (OSRAM)
JP2016503797A5 (OSRAM)
EA201400232A1 (ru) Фунгицидные замещенные 1-{2-[2-галоген-4-(4-галогенфенокси)фенил]-2-алкокси-2-циклилэтил}-1н-[1,2,4]триазольные соединения
JP2010506854A5 (OSRAM)
JP2016525130A5 (OSRAM)
JP2014511891A5 (OSRAM)
JP2018135343A5 (OSRAM)
AR074089A1 (es) Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2
WO2014174524A8 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
JP2017533263A5 (OSRAM)
RU2016133471A (ru) Композиции и способы для лечения диабета и заболеваний печени
JP2019516761A5 (OSRAM)
JP2017529389A5 (OSRAM)